corixa `gen süden - 500 Beiträge pro Seite

[wasweissichdenn]

corixa jetzt vorbörslich an der nasdaq minus 22%! ist da etwa auch was im busch??
wwid

[strateger]

@ wasweissichdenn


hallo, wo kann ich vorbörlich an der nasdaq sehen??

danke


strateger

[wasweissichdenn]

#2
hier: http://dynamic.nasdaq.com/dynamic/premarketma.stm
gruss wwid

[toller]

@wasweissichdenn

schau mal in dem anderen thread, Bexxar ist wieder nicht auf der liste der FDA für Februar. also gleicher absturz wie schon zuvor im August/september, als bekannt wurde, dass bexxar nicht im Dezember vorgestellt wird.

[Chris8888]

@ toller,

wo kannst du denn in die liste der FDA einsehen,wann über welche Zulassung entschieden wird?

Danke

[toller]

hi,

in einer meldung zu coria steht, dass der nächste Termin erst wieder im juni ist.

diese liste die du ansprichst kenn ich persönlich nicht. vielleicht findet sich was auf der page von www.fda.gov

ansonsten hab ich die infos nur aus den pressemeldungen unter

finance.yahoo.com symbol "crxa"

dort gibts auch ein forum, was allerdings genauso mit vorsicht zu geniessen ist wie alle aktienforen....

gruß

[toller]

zumindest haben die geschehnisse mal eben gezeigt, dass bei ws noch ein paar mehr corixa-aktionäre sind...119 mal wurde dieser thread gelesen heute seit wasweisich´s eröffnung um 15:26 uhr. bei 4 unterschiedlichen postern hier stecken hinter den 119 klicks bestimmt noch ein paar andere...

is nur mal so ne feststellung, weil ich mich manchmal gefragt habe, ob ich der einzige bin der anfang 2000 auf son tip von nem bekannten von nem bekannten von nem bekannten usw. gehört hat (bzw. bin ja eigentlich alter coulter aktionär, also nur durch die übernahme zu corixa gekommen) damals waren coulter´s Unterlagen zu bexxar bei der FDA zurückgewiesen worden aufgrund fehlender daten. purzelten sehr stark runter und bei 23Euro hat mir jemand erzählt, dass die nur was vergessen hätten, und bexxar echt große chancen hätte, zugelassen zu werden. bin da dann mal mit ner rel. kleinen position eingestiegen und hab nach und nach bei niedrigeren kursen verbilligt, leider nie bei den höheren kursen verkauft. so warte ich also nun zwei jahre auf den big bang....naja, anfänger-fehler damals.

mittlerweile bin ich aber ziemlich von dem unternehmen corixa überzeugt. die verzögerung ist doof, aber der kurs erholt sich wie ich zum glück jetzt sehe in usa schon wieder (musste bei -22% in usa glücklicherweise verschwinden)...

viel glück euch (uns) noch ;-)

[toller]

SOURCE: Corixa Corporation
Corixa to Present Melacine Data and Proposed Phase III Trial Design to the Oncologic Drugs Advisory Panel in February
SEATTLE--(BW HealthWire)--Jan. 15, 2002--Corixa Corporation (Nasdaq:CRXA - news), a developer of immunotherapeutics, today announced it has been informed by the FDA that the Oncologic Drugs Advisory Committee (ODAC) will discuss the appropriate study design and control for a proposed second Phase III trial of Corixa`s Melacine® melanoma vaccine at 12:30 p.m. EDT on February 27, 2002 in Bethesda, Maryland.

Corixa`s presentation to ODAC will include results from its completed first Phase III trial of Melacine vs. observation in patients with Stage II melanoma, as conducted by the Southwest Oncology Group (SWOG).

In October, 2001, Corixa announced that FDA approval of Melacine in the United States would require a second Phase III clinical trial in class I MHC HLA A2 and C3 positive patients.

In June 2001, Corixa announced the completion of a 17 month data sweep associated with the completed pivotal trial of Melacine vaccine for Stage II melanoma. In an effort to provide the FDA and its advisory panel reviewers with as up-to-date a data package as possible, Corixa committed to obtain additional mortality and disease recurrence data on as many patients as possible in the database, prior to proceeding with completion of a BLA filing.

Re-analysis of overall disease free survival including these new data, showed that Melacine continues to provide an improvement in overall disease free survival, although the statistical significance of that conclusion was lost (p is greater than 0.05). However, analysis of clinical benefit following completion of the data sweep in patients who were positive for expression of either Class I MHC HLA A2 or C3 genes continued to show a highly statistically significant clinical benefit of Melacine vs. observation in terms of increased disease free survival (p=0.005). Furthermore, Corixa`s analyses demonstrated a statistically significant improvement in overall survival in class I MHC HLA A2 or C3 positive patients that received Melacine vs. observation (p=0.003).

About Melacine

Melacine melanoma vaccine consists of lysed (broken) cells from two human melanoma cell lines combined with Corixa`s proprietary Detox(TM) adjuvant. Detox adjuvant includes MPL® adjuvant (monophosphoryl lipid A) and mycobacterial cell wall skeleton, both of which activate the human immune system in the context of vaccination. Melacine vaccine is administered as a two-shot vaccination delivered as four six-month cycles, each consisting of 10 treatments followed by a three-week rest.

[toller]

und noch ne neue nachricht:

Tuesday January 15, 4:01 pm Eastern Time
Press Release
SOURCE: Corixa
Corixa and Beaufour Ipsen Collaborate to Develop and Commercialize Corixa`s AnergiX.MG technology For the Treatment of Myasthenia Gravis
SEATTLE & PARIS--(BW HealthWire)--Jan. 15, 2002--Corixa Corporation (Nasdaq:CRXA - news), a developer of immunotherapeutics, and Beaufour Ipsen Group, a European global pharmaceutical company, today announced a license, development and commercialization agreement for Corixa`s AnergiX.MG(TM) technology for the treatment of myasthenia gravis, a chronic autoimmune neuromuscular disease that causes varying degrees of weakness of the skeletal muscles of the body.

Under the terms of the agreement, Corixa will provide Beaufour Ipsen with exclusive worldwide rights to develop and market its AnergiX.MG technology for the treatment of myasthenia gravis. Beaufour Ipsen will manage product development, including clinical trials and regulatory submissions. Beaufour Ipsen will pay Corixa an up-front license fee, guaranteed research support, success-based milestone payments and royalties in the event of Beaufour Ipsen product sales. The collaboration will be overseen by a joint steering committee made up of representatives from both companies. Further details of the agreement were not disclosed by either party.

``Our agreement with Beaufour Ipsen demonstrates the continued value of the AnergiX technology originally obtained in the Anergen acquisition and further extends the therapy potential of Corixa technology,`` stated Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. ``We hope that our collaboration with Beaufour Ipsen will provide a much needed treatment for those suffering from this debilitating neuromuscular disorder.``

``We are excited to be working with Corixa to develop the AnergiX.MG technology which will further expand our dedication to the treatment of neuromuscular diseases,`` said Jacques-Pierre Moreau, group vice president, Research & Development of Beaufour Ipsen. ``We share in Corixa`s commitment to discovering and developing innovative technologies and look forward to the possibility of developing a novel treatment for myasthenia gravis patients.``

About Myasthenia Gravis

Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. It occurs when normal communication between the nerve and muscle is interrupted at the neuromuscular junction -- the place where nerve cells connect with the muscles they control. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. Acetylcholine travels through the neuromuscular junction and binds to acetylcholine receptors that are activated and generate a muscle contraction. In myasthenia gravis, antibodies block, alter, or destroy the receptors for acetylcholine at the neuromuscular junction that prevents the muscle contraction from occurring.

About Corixa

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a stand-alone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, Bexxar®, a monoclonal antibody conjugated to a radioisotope.

The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Washington, with additional operations in Hamilton, Montana and South San Francisco, California. For more information, please visit Corixa`s Website at www.corixa.com or call the company`s investor relations information line at 1.877.4CORIXA or 877/426-7492.

About Beaufour Ipsen

Beaufour Ipsen is an independent European ethical pharmaceutical company which, aside from a traditional line of natural products (Gingko Biloba extracts and clays), has successfully developed and commercialized a range of specialist and biotech-derived pharmaceuticals. Beaufour Ipsen is a leader in the development and production of controlled release formulation for therapeutic peptides used in the treatment of hormone responsive illnesses. Beaufour Ipsen markets Dysport, a brand of Botulinum toxin prescribed for the treatment of motor disorders and muscle spasticity. The company has sales in 80 countries

[toller]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[toller]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[toller]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[toller]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[toller]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[toller]

Press Release
SOURCE: Corixa Corporation
Corixa Reports Strong Fourth Quarter and Year-End Results
Revenue in 2001 Increased 57 Percent
Results Within Provided Earnings Estimates
SEATTLE--(BW HealthWire)--Jan. 31, 2002--Corixa Corporation (Nasdaq:CRXA - news), a developer of immunotherapeutics, today announced results for the fourth quarter and year ended December 31, 2001.

For the fourth quarter of 2001, Corixa reported total revenue of $14.9 million compared with total revenue of $11.6 million for the fourth quarter of 2000. Net loss applicable to common stockholders for the fourth quarter of 2001 was $34.1 million, compared to $646.7 million for the fourth quarter of 2000. The change in the fourth quarter net loss compared with a year ago was due primarily to a one-time charge of $629.7 million for in-process research and development related to Corixa`s December 22, 2000 acquisition of Coulter Pharmaceutical, Inc. Diluted net loss per common share for the fourth quarter of 2001 was $0.83 compared with diluted net loss per common share of $27.81 for the fourth quarter of 2000. Excluding acquisition related charges such as intangible and deferred compensation amortization, net loss applicable to common stockholders for the fourth quarter of 2001 was $18.8 million, which represents a net loss per share of $0.46.

For fiscal year 2001, Corixa`s total revenue was $58.1 million, compared to total revenue of $37 million for fiscal year 2000. Net loss applicable to common stockholders was $149.8 million compared with $677.1 million for fiscal year 2000. The change in the net loss compared with a year ago was primarily due to a one-time charge of $629.7 million for in-process research and development related to Corixa`s December 22, 2000 acquisition of Coulter Pharmaceutical Inc. Diluted net loss per common share for 2001 was $3.66 compared to diluted net loss per common share of $32.30 for 2000. Excluding acquisition related charges such as intangible and deferred compensation amortization, net loss applicable to common stockholders for fiscal year 2001 was $80.4 million, which represents a net loss per share of $1.96.

The increase in revenue for the fourth quarter of 2001 and fiscal year 2001 was primarily due to revenue recognized from collaborative agreements with GlaxoSmithKline, Organon, Wyeth Lederle Vaccines and Zenyaku Kogyo. At December 31, 2001, Corixa had $121 million in cash, cash equivalents and investments. In addition to the $121 million, Corixa secured a $75 million equity line of credit from BNY Capital Markets, a subsidiary of the Bank of New York, that has not yet been accessed.

``We are pleased with our progress in 2001 -- progress marked by advancement in the clinic, continued innovation in the lab and expanded development and marketing collaborations,`` said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. ``We continued to make progress in moving multiple programs through various stages of clinical study and benefited by expanding our discovery efforts in new disease fields. In addition, we continued to strive to diminish the impact of adverse market and industry trends with the addition of new collaborations and opportunities as demonstrated through our Bexxar and Metastron agreements with Amersham Health, our enhanced adjuvant license agreement with Wyeth Lederle Vaccines and our recently announced license and collaboration agreement with Beaufour Ipsen. Our cash position remains strong, affording us an opportunity to further expand our product development in the coming year and deliver on our goal of bringing leading immunotherapies to patients worldwide.``

2001 in Review

Products and Programs in Development

Bexxar®, an investigational radioimmunotherapy for the treatment of non-Hodgkin`s lymphoma, continued to demonstrate improved clinical responses in a variety of study settings while it remains under review for approval by the U.S. Food and Drug Administration (FDA). For example, Bexxar demonstrated improved clinical responses in chemotherapy refractory non-Hodgkin`s lymphoma patients in a study conducted at the University of Michigan Cancer Center and published in the Journal of Clinical Oncology. Research presented at the American Society of Hematology 43rd annual meeting also showed durable responses with Bexxar alone or when used following various chemotherapies for treatment of low-grade non-Hodgkin`s lymphoma.

Corixa also recently announced that the Oncologic Drugs Advisory Committee will review in February 2002, completed Phase III trial data and a proposed second Phase III clinical trial design for Melacine®, Corixa`s therapeutic melanoma vaccine. Corixa announced in February 2001, Melacine`s commercial availability in Canada.

In addition to its near-term oncology programs, Corixa continued to demonstrate its commitment to product developments for autoimmune and infectious diseases with the progress of additional clinical studies for psoriasis and hepatitis B. Moreover, Corixa reported positive preliminary Phase III results for its RC-529 synthetic adjuvant in vaccination to prevent hepatitis B infection. Phase II clinical trial results for PVAC(TM) treatment suggested that the therapy was well tolerated and suggested clinical benefit at certain doses in patients suffering from psoriasis.

Partnerships

Corixa also entered into several new relationships in 2001 and reported progress and expansion of existing collaborations, including agreements with Kirin Brewery Co., Ltd., SPAWAR, Organon, Amersham Health, Wyeth Lederle Vaccines, and the pharmaceutical division of Japan Tobacco Inc, as well as Beaufour Ipsen in January 2002.

Technology

Corixa continued to strengthen its patent estate by receiving multiple patents from the U.S. Patent and Trademark Office. Some of the 32 U.S. patents Corixa received in 2001 included claims covering a chemokine receptor polypeptide for vaccination therapy of certain autoimmune disease, a chlamydia vaccine, and a method potentially useful in establishing the optimal radiation dose given to a patient based on the patient`s specific traits -- a method used in administering Bexxar.

Conference Call

Corixa`s earnings conference call and web cast will take place on January 31, 2002 at 8 a.m. ET/5 a.m. PT. Participants can access the call by dialing 888/202-2422 (domestic) and 913/981-5592 (international), passcode 595669. Web cast participants can sign up at the Investors page of Corixa`s web site at http://www.corixa.com/default.asp?pid=investor. Individuals who are unable to participate in the conference call can access a recorded rebroadcast by going to the Investors page of Corixa`s web site (www.corixa.com) or by dialing 888/203-1112 (domestic) and 719/457-0820 (international), passcode 595669. The call will be rebroadcast until 12 a.m. ET, February 5, 2002.

About Corixa

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a stand-alone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development.

The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Washington, with additional operations in Hamilton, Montana and South San Francisco, California. For more information, please visit Corixa`s Website at www.corixa.com or call the company`s investor relations information line at 1.877.4CORIXA or 877/426-7492.

Forward Looking Statements

Except for the historical information presented, certain matters discussed in this press release, including statements about our future product development, statements about expected regulatory approval timelines, statements about the potential efficacy and safety of our product candidates and statements about our future operating results are forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made. They are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Factors that could affect Corixa`s actual results include, but are not limited to, the risk we are unable to commercialize our product candidates, the risk of delay or rejection of our product candidates in the regulatory approval process, the risk that clinical trials of our product candidates do not successfully demonstrate the safety or efficacy of those product candidates, the risk that our future operating results will vary from quarter to quarter and the other ``Factors Affecting Our Operating Results, Our Business and Our Stock Price,`` described in Corixa`s Quarterly Report on Form 10-Q for the quarter ended September 30, 2001, copies of which are available from Corixa`s investor relations department. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.


Corixa Corporation

Consolidated Statement of Operations
(In thousands except per share data)

(Unaudited)

Three months ended Twelve months ended
December 31, December 31,
2001 2000 2001 2000
-------------------------------------------
Revenue:
Collaborative
agreements $14,150 $10,919 $55,128 $34,643
Government grants 741 656 2,937 2,331
------- ------- ------- -------
Total revenue 14,891 11,575 58,065 36,974

Operating expenses:
Research and
development 30,154 16,705 138,621 61,911
Sales, general and
administrative 4,479 2,195 18,866 6,694
Unconsolidated
joint business 1,577 -- 3,495 --
Intangible
amortization 14,398 2,167 57,625 4,499
Acquired in-process
research and
development -- 629,700 -- 629,700
------- ------- ------- -------
Total operating
expenses 50,608 650,767 218,607 702,804
------- ------- ------- -------
Loss from operations (35,717) (639,192) (160,542) (665,830)
Interest income 1,433 1,878 9,349 5,378
Interest expense (447) (294) (2,295) (810)
Other income 486 286 5,451 431
------- ------- ------- -------
Loss before cumulative
effect of change in
accounting principle (34,245) (637,322) (148,037) (660,831)
Cumulative effect of
change in accounting
principle -- -- -- (6,338)
------- ------- ------- -------
Net loss (34,245) (637,322) (148,037) (667,169)

Preferred stock
dividend 145 (9,419) (1,730) (9,887)
------- ------- ------- -------
Net loss applicable
to common
stockholders $(34,100) $(646,741) $(149,767) $(677,056)
======== ========= ========= =========
Basic and diluted loss
per share before
cumulative effect of
change in accounting
principle $(0.83) $(27.81) $(3.66) $(32.00)
Cumulative effect of
change in accounting
principle per share -- -- -- (0.30)
Basic and diluted net
loss per common share $(0.83) $(27.81) $(3.66) $(32.30)
======== ========= ========= =========
Shares used in
computation of basic
and diluted net loss
per common share 41,311 23,254 40,961 20,961
======== ========= ========= =========


December 31, December 31,
2001 2000
--------------------------------
Balance Sheet Data:
Cash, cash equivalents and
securities available-for-sale $121,064 $197,078
Working capital 53,946 146,844
Total assets 367,382 504,334
Long-term obligations less
current portion 27,657 33,422
Accumulated deficit (903,242) (755,205)
Total stockholders` equity 281,765 404,575


Three months ended Twelve months ended
December 31, 2001 December 31, 2001
---------------------------------------
Reconciliation of net loss
to net loss excluding Coulter
acquisition related charges:

Net loss applicable to
common stockholders $(34,100) $(149,767)
Intangible amortization 13,660 54,675
Deferred compensation
amortization 1,612 14,648
-------- ---------
Net loss excluding
acquisition related charges $(18,828) $(80,444)
======== =========
Basic and diluted net loss
per share excluding acquisition
related charges $(0.46) $(1.96)
-------- ---------

[toller]

tja, sieht so aus, als ob wir das rennen nun endgültig verloren haben:

IDEC Pharmaceuticals (NasdaqNM:IDPH - news) rose as the company said the U.S. Food and Drug Administration approved its cancer drug Zevalin. IDEC shares jumped to $59.72 from a close of $56.01 on the Nasdaq.


was für ein ....und bexxar ist noch nicht mal besprochen worden. denke der markt wird schön von IDEC abgegrast. mist.

[okujawa]

Corixa unter 10 $ geschlossen, wenn es heute nicht wieder darüber geht gute Nacht.
cu
ok

[okujawa]

Corixa unter 10 $ geschlossen, wenn es heute nicht wieder darüber geht gute Nacht.
cu
ok

[toller]

heute könnte was kommen. 828.000 stück gehandelt und ein anstieg von 15,x prozent. mal sehen was ab 15:30 passiert.

daumen drücken, es wird langsam mal zeit...;-)

[puhvogel]

Versucht noch zu verkaufen!
Die Ablehnung der FDA überrascht mich aber auch kein bisschen.

Corixa Receives Complete Review Letter On BEXXAR
SEATTLE--(BW HealthWire)--March 13, 2002--Corixa Corporation (Nasdaq:CRXA - news), a developer of immunotherapeutics, today announced the receipt of a complete review letter from the U.S. Food and Drug Administration (FDA) regarding the Biological License Application (BLA) for BEXXAR® (tositumomab, iodine I-131 tositumomab), an investigational radioimmunotherapy for the treatment of low-grade or transformed low-grade non-Hodgkin`s lymphoma.

Bexxar is being co-developed by Corixa and GlaxoSmithKline in the United States.

In the Complete Review letter received in the evening of March 12, 2002, the FDA stated that in its opinion, Corixa`s September 10, 2001 response to the Agency`s March 16, 2001 Complete Review letter did not provide sufficient evidence of the safety and net clinical benefit of BEXXAR and further stated that additional clinical studies will be required to provide such evidence. Regarding Corixa`s prior request for Accelerated Approval, the letter stated that the data reviewed by the Agency do not provide sufficient evidence that BEXXAR addresses an unmet medical need. Additionally, the letter stated that within 10 days from its receipt, Corixa must either amend its application, notify the Agency of its intent to file an amendment, withdraw the application or request an opportunity for a hearing on whether there are grounds for denying approval of the application. Corixa will formally request a meeting with representatives of the Agency for further discussion of a regulatory path for BEXXAR. It is expected that this meeting will occur within the next 45 days.

``We are extremely disappointed with the FDA`s decision and intend to promptly pursue resolution with our partner, GlaxoSmithKline and the Agency,`` stated Steven Gillis, Ph.D., Corixa chairman and chief executive officer. ``We are formally requesting a meeting with the FDA and hope to reach mutual agreement on the specific steps still necessary for approval. We will provide additional guidance as to the regulatory pathway for BEXXAR after further discussions with GlaxoSmithKline and the FDA.``

[puhvogel]

5 $ jetzt.

[okujawa]

So schnell kann es gehen! Ich hab zum Glück nur eine kleine
Position und bei derzeit -50% verkaufe ich sie nicht mehr, obwohl die Aussichten für Corixa,was Bexxar betrifft, nicht gerade rosig sind.
Es wird sicherlich noch etwas runter gehen und dann schlag ich nocheinmal zu, nehme die, hoffentlich folgende, Kurserholung mit und gleiche damit einen Teil der Verluste aus.Bestes Beispiel für dieses Szenario ist Imclone, da lief es ähnlich.
cu
ok

[puhvogel]

Wenn ich ehrlich bin, wundere ich mich, dass Corixa so wenig gefallen ist, gerade wenn ich das mit dem Sepracor-Debakel vergleiche. Sepracor ist davon nicht so stark betroffen wie Corixa. Die relativ starke Gegenbewegung spricht aber kalr eine andere Sprache. Vielleicht kauft der Gates dazu.
Melacine ist auch ein grosser Wackelkandidat.

[axel60]

Hi,
Corixa hat noch andere gute Entwicklungen in der Hinterhand.
Nur die Ruhe bewahren. Kommt Zeit, kommt auch die FDA-Zulassung .

Axel 60

[toller]

ich bin erstmal so enttäuscht, echt schade.

ich überlege auch, ob ein nachkauf jetzt sinnvoll ist. oder ob die aktie erstmal für ein paar wochen flach liegt. normalerweise gings ja nach so schlachten nachrichten bei corixa immer recht schnell wieder nach oben, aber diesmal....

komisch nur das zevalin (IDPH) so einfach durchgekommen ist beim FDA, obwohl es das problem gab, dass wohl einige patienten die zusätzlich mit zevalin behandelt wurden, gestorben sind. hoffe ich erinnere mich da richtig, aber da gabs mal ein problem.

so etwas ist von bexxar nicht bekann, allgemein sprechen die fachleute von einer sehr viel höheren heilungsquote und auch von einer breiteren anwendbarkeit.

naja, abwarten

[puhvogel]

@toller: Wenn dir das wichtig ist, kann ich mir mal die Begründung der Kommission durchschauen.
Im Netz habe ich folgende Meldung zum Thema gefunden
http://www.biospace.com/articles/biotech_sage082901.cfm
"Zevalin may face competition from Corixa`s drug, Bexxar. Both Corixa and GlaxoSmithKline are waiting for the advisory committee to review Bexxar for FDA approval. A race may seem to exist between Zevalin and Bexxar as to whom will get to the market first to garner market share. However, when comparing the two drugs, the advantage that Zevalin has over Bexxar is the ease of use for the physician. Thus, as far as BioTech Sage Report ("BSR") is concerned, even if the FDA approves Bexxar, the treatment may have a difficult time gaining market acceptance. IDEC`s drug strengthens its position as the leader for treating various types of lymphoma. "

[toller]

wow, ich hoffe ihr habt alle bei 6,4 oder so mächtig zugeschlagen. ihc leider nicht.

jedenfalls startet corixa heute an der nasdaq mit einer Transaktion von 110,100 Stück in der ersten minute.

den deal mit j&J hatte ich auch heute morgen schön bei yahoo gelesen, aber irgendwie nicht gleich an Johnson und johnson gedacht. steht etwas weiter unten im artikel.
corixa war mir einfach für einen nachkauf noch zu heiss ;-((

na dann mal abwarten wie sie heute laufen. pre-market waren sie wohl schon auf 6.6 $

infos von finance.yahoo.com

[toller]

nach 20 minuten handel 360000 Stück. mal schauen wo wir enden..

[toller]

hi,

falls jemand noch dabei ist oder wieder dabei ist, gestern usa +25% bei ca. 1,4 mio gehandelten aktien

allerdings
After Hours Change** -1.00 -16.00%.....

mal abwarten

morgen vor börsenstart in usa ist ne Konferenz

Corixa Corp. First Quarter Earnings and Select Program Update Conference Call
CONFERENCE CALL/WEBCAST ALERT
SEATTLE--(BW HealthWire)--May 14, 2002-- Corixa Corporation (Nasdaq:CRXA - News), will hold a live conference call/webcast to discuss the company`s first quarter financial results and provide an update on select programs. Earnings will be announced in a press release on Wednesday, May 15 before U.S. financial markets open.


Conference Call Date and Time:
Wednesday, May 15, 2002
8:30 a.m. ET/5:30 a.m. PT

[toller]

Corixa says FDA to review of cancer drug Bexxar

SEATTLE, June 27 (Reuters) - Pharmaceutical firms Corixa Corp. (NasdaqNM:CRXA - News) and Britain`s GlaxoSmithKline Plc (NYSE:GSK - News; London:GSK.L - News) on Thursday said a federal agency has agreed to a new review of cancer drug Bexxar.
ADVERTISEMENT



The companies said the U.S. Food and Drug Administration granted the appeal to review the regulatory status of Bexxar, which targets non-Hodgkin`s lymphoma, the fifth most deadly cancer killer. The drug is being developed by Corixa and GlaxoSmithKline.

In March, the FDA rejected Corixa`s application for Bexxar, saying it needed more proof of the drug`s effectiveness. The rejection meant Corixa would have to conduct new trials on the drug. Corixa appealed that decision in May. Thursday`s FDA action is the result of that appeal.

Corixa said it will submit additional information on the drug and will present data on Bexxar`s effectiveness at a future meeting of the FDA`s Oncologic Drugs Advisory Committee. The FDA indicated it is "highly likely" that such a review will happen by the end of the year, Seattle, Washington-based Corixa said.

Shares of Corixa closed at $5.62 in Wednesday Nasdaq trading. U.S.-traded shares of GlaxoSmithKline closed at $41.70 in Wednesday trading on the New York Stock Exchange.

[Kurumba]

run for the hills shorts - your days are numbered